Category: Featured

Race Oncology is very pleased to announce that it has executed a Named Patient Program (NPP) distribution and sales agreement in Israel with TrueMed Ltd. According to Race, TrueMed is a pharmaceutical distributor with experience in driving NPPs in Israel.…

Race Oncology is pleased to announce it has executed a services agreement with BioSynergy Partners LLC (BioSynergy) to pursue licensing and other deals for Bisantrene (the ‘Agreement’). BioSynergy is a transaction consulting business owned by Dr John Cullity, a non-executive…

CEO Peter Molloy spoke with Finance News Network about Bisantrene and Race Oncology’s future prospects.

Race Oncology is pleased to announce that it has executed an agreement with Mr Tom Lee to assist Race with partnering and funding opportunities in the US, with a focus on Houston, Texas. Mr Lee is well-connected to the MD Anderson…

Race Oncology is pleased to announce it has executed an agreement with Washington D.C – based advisory firm, NSF Health Sciences, to facilitate its IND1 filing in the US for leukaemia drug Bisantrene. Under the agreement, NSF Health Sciences (“NSF”)…

Race Oncology is pleased to announce that it has received a letter from the FDA advising that Bisantrene has been granted Rare Paediatric Disease (RPD) designation for the treatment of childhood Acute Myeloid Leukaemia (AML). The RPD designation means Bisantrene has…

The poster below details the long-term survival case report of two paediatric relapsed or refractory Acute Myeloid Leukemia patients treated with Bisantrene Combination Therapy.

Race Oncology is pleased to announce that approval has been received from the Medicines and Healthcare products Regulatory Agency (MHRA) for importation and distribution of Bisantrene as an unlicensed medicine in the UK. The letter from the MHRA was received…

Race Oncology is pleased to announce a case report describing the successful use of Bisantrene to treat childhood relapsed/refractory AML (Acute Myeloid Leukaemia). The report will be published at a forthcoming oncology conference in France. The case report describes two…

Race Oncology Non-Executive Director Dr. John Cullity speaks with Proactive Investors about the company’s cancer chemotherapy drug, Bisantrene.